title: Thrombophilic risk factors in patients with central retinal vein occlusion.
abstract: Few and contrasting data are available on the prevalence of hemostatic risk factors in patients with central retinal vein occlusion (CRVO). Aim of this study was to investigate the metabolic and inherited risk factors for venous thrombosis in 100 CRVO patients (age: 59 yrs; range 18-77) and in 100 controls (age: 56 yrs; range 18-84). In patients homocysteine (Hcy) levels were significantly higher than in controls and were affected by the C677T methylenetetrahydrofolate reductase (MTHFR) polymorphism (p < 0.001). The prevalences of activated protein C resistance (APCR), factor V Leiden positivity, elevated PAI-1 and Lp(a) levels were significantly higher in patients with respect to controls. At multivariate analysis, only hyperhomocysteinemia (OR 11, 95% CI 3.6-36.2; p < 0.0001) and elevated PAI-1 levels (OR 8.9, 95% CI 3.5-41.3; p < 0.01), in addition to hypertension (OR 40.5, 95% CI 8.6-188.8; p < 0.00001) and hypercholesterolemia (OR 3.1, 95% CI 1.6-20.5; p < 0.05), were independent risk factors for CRVO. These data demonstrate a potential role of hemostatic risk factors in the pathophysiology of CRVO.
authors.affiliation: Dept Area Critica Medico-Chirurgica, Thrombosis Center, Az Ospedaliera Careggi, University of Florence, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Marcucci
authors.forename: L
authors.initials: L
authors.lastname: Bertini
authors.forename: B
authors.initials: B
authors.lastname: Giusti
authors.forename: T
authors.initials: T
authors.lastname: Brunelli
authors.forename: S
authors.initials: S
authors.lastname: Fedi
authors.forename: A P
authors.initials: AP
authors.lastname: Cellai
authors.forename: D
authors.initials: D
authors.lastname: Poli
authors.forename: G
authors.initials: G
authors.lastname: Pepe
authors.forename: R
authors.initials: R
authors.lastname: Abbate
authors.forename: D
authors.initials: D
authors.lastname: Prisco
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001779:Blood Coagulation Factors / Q000032:analysis / Q000235:genetics; D002561:Cerebrovascular Disorders / Q000453:epidemiology; D015897:Comorbidity; D003327:Coronary Disease / Q000453:epidemiology; D003920:Diabetes Mellitus / Q000453:epidemiology; D005165:Factor V / Q000032:analysis; D005260:Female; D020022:Genetic Predisposition to Disease; D006487:Hemostasis; D006801:Humans; D006937:Hypercholesterolemia / Q000453:epidemiology; D020138:Hyperhomocysteinemia / Q000453:epidemiology; D006973:Hypertension / Q000453:epidemiology; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008875:Middle Aged; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000235:genetics; D017354:Point Mutation; D011446:Prospective Studies; D011516:Prothrombin / Q000235:genetics; D012170:Retinal Vein Occlusion / Q000453:epidemiology / Q000209:etiology*; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology; D019851:Thrombophilia / Q000453:epidemiology* / Q000235:genetics; D020246:Venous Thrombosis / Q000453:epidemiology
chemical_list: D001779:Blood Coagulation Factors; C095381:factor V Leiden; D005165:Factor V; D011516:Prothrombin; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2)